Splicing dysregulation has emerged as a novel hallmark of breast cancer, with oncogenic splicing variants of HER2, ER, BRCA1, AIB1, and other tumor- and metabolism-related genes linked to heightened malignancy, poor prognosis, and treatment resistance. This evidence concerns the gene ERBB2 and breast carcinoma.